Carlos E de Andrea

20PUBLICATIONS
193CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Sep 07, 2026
TNFR1 expression on cancer cells mediates immune escape and an immunosuppressive microenvironment.

|Aug 25, 2026
CD137 agonists in mice suppress germinal center responses by increasing the immunosuppressive activity of follicular regulatory T-cells.

|Aug 06, 2026
Antibody-Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors.

|Mar 11, 2026
Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axis.

Bruno Beernaert, Rose L Jady-Clark, Parin Shah

|Jan 16, 2026
Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab.

Miguel F Sanmamed, Carlos E de Andrea, David Ruiz-Guillamon

|Nov 13, 2025
The Proteomic Landscape of CTNNB1 Mutated Low-Grade Early-Stage Endometrial Carcinomas.

Alvaro Lopez-Janeiro, Emilia Brizzi, Ignacio Ruz-Caracuel

Pageof 4

Frequent Collaborators

11 joint publications

Ignacio Melero

8 joint publications

Pedro Berraondo

7 joint publications

Alvaro Teijeira

7 joint publications

Carlos Luri-Rey